Why Horizon Therapeutics Stock Is Up Today
Shares of Horizon Therapeutics (NASDAQ: HZNP) are up by 17% as of 11:54 a.m. EDT on Wednesday, after the company reported better-than-expected second-quarter financial results before the market opened today.
During the second quarter, Horizon Therapeutics' net sales soared by 44% year over year to $462.8 million. The company's top line also came in well ahead of the $332.45 million analysts were expecting. The recent commercial launch of Tepezza, a treatment for thyroid eye disease (TED) approved by the U.S. Food and Drug Administration (FDA) in January, was one of the main reasons behind Horizons Therapeutics' strong sales growth during the quarter.
Image source: Getty Images.
Source Fool.com
